63341 Real-World Comorbidities, Treatment Use, and Healthcare Resource Utilization Among Elderly Patients With Prurigo Nodularis Initiating Dupilumab in the US
Gil Yosipovitch(University of Miami), Kwinten Bosman(Regeneron (United States)), Joseph Zahn(Regeneron (United States)), Danielle Sienko, Tiange Yu, Catherine Allende, Kirsten Walker(Queen's University), Simmi Wiggins(Sanofi (United Kingdom)), Danielle L. Isaman(Aetion (United States)), Daniel Butler(Torbay and South Devon NHS Foundation Trust), Natalia Petruski‐Ivleva(AVEO Oncology (United States))
Cited by 0
Related Papers
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
|British Journal of Dermatology|2019|384
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
|New England Journal of Medicine|2020|280
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254
Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions
|Acta Dermato Venereologica|2019|189